333 SHORT FORM-36 (SF-36) AND EUROQOL-5 DIMENSION (EQ-5D) RESULTS FROM RANDOMIZED, DOUBLE-BLIND PHASE 3 STUDIES OF TAPENTADOL PROLONGED RELEASE (PR) IN PATIENTS WITH MODERATE TO SEVERE CHRONIC NOCICEPTIVE AND NEUROPATHIC PAIN  by Lange, R. et al.
Poster Presentations / Osteoarthritis and Cartilage 18, Supplement 2 (2010) S45–S256 S147
While the WOMAC pain and physical function scores indicated a mild to
moderate level of pain and disability over the past 48 hours, prospective
data collection (Participant Diary) detected higher levels of knee pain
when the highest score reported of the 7 day period was utilized (highest
7-day knee pain). Further, the prospective 7-day Participant Diary also
demonstrated almost half of the study participants (44%) with a mean
global assessment of their knees as only ‘fair’ or ‘poor’.
A simple Participant Diary requiring daily recording of knee pain speciﬁed
as ‘at its worst’ on a 11 point rating scale over one week may provide an
inexpensive, robust and responsive outcome measure in long term clinical
trials compared to retrospective reporting of pain (past 48 hours) but
without descriptive speciﬁcity.
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VALIDATION OF DIGITALIZED HEALTH STATUS QUESTIONNAIRES
FREQUENTLY USED IN THE MONITORING OF OSTEOARTHRITIS: A CROSS
SECTIONAL STUDY
H.R. Gudbergsen Sr.
The Parker Inst., Frederiksberg, Capital Region, Denmark
Purpose: To validate digitalized Health Status Questionnaires (HSQs) used
for sampling Patient Reported Outcomes for knee osteoarthritis (KOA) pa-
tients, employing newly developed freeware on touch screens. Furthermore
to examine the effect of patient characteristics on differences between
HSQ-versions.
Methods: Touch screen answers were compared to answers on paper
versions of the most commonly used HSQs in the clinical management of
KOA, and participants were recruited from an ongoing in-house KOA trial
(the CAROT-study; ClinicalTrials.Gov Identiﬁer: NCT00655941). 20 female
participants, mean age 67 (SD 7), completed KOOS, SF-36, ADL Taxonomy,
Physical Activity Scale, VAS pain, function and patient global and Pain
Detect, and the trial proﬁle ensured testing of only one HSQ at the time
in a repeated randomized cross-over design. The two HSQ versions (paper
and touch screen) were completed with a 5 min. interval and between
each HSQ patients had a 5 min. break. Mean values for each version,
mean differences (95% CI), pooled means, medians, median differences,
Minimal Important Differences and Spearman correlation coeﬃcients were
calculated for all HSQs including relevant subscales.
Results: Correlations between touch screen and paper version of SF-36
were 0.92 for the physical component summary scale and 0.81 for the
mental component summary scale. Similar correlations for KOOS ranged
from 0.88 to 0.98, and the other instruments were tested with comparable
results. When analysing mean and median differences we found no consis-
tent pattern in differences between the two measures, nor were there any
systematic patterns in the differences between HSQ-versions. No signiﬁcant
inﬂuence was observed of age, former computer experience or level of
education on differences between the two HSQ-versions. The participants
did not need further help or explanations when ﬁlling out questionnaires
on screen and found the process easier than ﬁlling in paper versions of the
questionnaire. 16 of 20 overall preferred the touch screen version.
Correlation between paper- and touch-screen versions
Paper version Spearmans Correlation Touch Screen
Coeﬃcient Version
KOOS 0.97 KOOS
VAS pain 0.89 VAS pain
VAS function 0.87 VAS function
VAS patient global 0.78 VAS patient global
SF-36Physical Component Summary Scale 0.92 SF-36Physical Component Summary Scale
SF-36Mental Component Summary Scale 0.81 SF-36Mental Component Summary Scale
Physical Activity Scale 0.84 Physical Activity Scale
Pain Detect1 0.97 Pain Detect1
Pain Detect2 0.96 Pain Detect2
Pain Detect3 0.95 Pain Detect3
Pain Detect4 0.86 Pain Detect4
Pain Detect5 0.88 Pain Detect5
Pain Detect6 0.91 Pain Detect6
ADL Taxonomia 0.95 ADL Taxonomia
Conclusions: The digitalized HSQs on touch screen gave statistically com-
parable results to answers given on a paper version of the same HSQs. Use
of electronic questionnaires gives a safer and more precise data collection
due to direct registration of answers, and implementation as well as use of
this freeware is feasible for patients
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FROM RANDOMIZED, DOUBLE-BLIND PHASE 3 STUDIES OF TAPENTADOL
PROLONGED RELEASE (PR) IN PATIENTS WITH MODERATE TO SEVERE
CHRONIC NOCICEPTIVE AND NEUROPATHIC PAIN
R. Lange1, B. Lange1, A. Greene2, A. Okamoto2, M. Etropolski2,
J. Ashworth1
1Global Dev., Grünenthal GmbH, Aachen, Germany; 2Johnson & Johnson
Pharmaceutical Res. & Dev., L.L.C., Raritan, NJ
Purpose: To summarize SF-36 and EQ-5D health survey results from four
15-week, double-blind phase 3 studies of tapentadol PR in patients with
osteoarthritis (OA) pain (NCT00421928 [OA study 1] and NCT00486811
[OA study 2]), low back pain (NCT00449176), and pain related to diabetic
peripheral neuropathy (DPN; NCT00455520).
Methods: In the OA and low back pain studies, patients received placebo,
tapentadol PR (100-250 mg bid), or oxycodone HCl controlled release (CR;
20-50 mg bid) during a 3-week titration period and a 12-week maintenance
period. In the DPN study, patients received tapentadol PR (100-250 mg bid)
during a 3-week open-label titration period; patients with at least a 1-point
improvement in pain intensity (11-point numerical rating scale [NRS])
were randomized to receive placebo or their optimal dose of tapentadol
PR (determined in the titration period) during a 12-week double-blind
maintenance period. SF-36 and EQ-5D health survey questionnaires were
used to assess health status. The SF-36 consists of 8 dimensions (physical
functioning, role-physical, bodily pain, general health, vitality, social func-
tioning, role-emotional, and mental health) measured on a 0 to 100 NRS
(0 = being in poor health to 100 = being in good health) and summarized
as physical component and mental component summaries. The EQ-5D con-
sists of 5 dimensions (mobility, self-care, usual activities, pain/discomfort,
and anxiety/depression), which are measured using 3 possible levels (“no
problems,” “some problems,” and “extreme problems”) and summarized
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an overall EQ-5D health status index score. SF-36 and EQ-5D data from the
2 OA studies and the low back pain study were also pooled for analysis;
comparisons versus placebo were prespeciﬁed.
Results: The intent-to-treat populations contained the following numbers
of patients: low back pain study, n = 965; OA study 1, n = 1023; OA
study 2, n = 987; DPN study, n = 389; pooled analysis, n = 2968. In the
low back pain study and OA study 1, mean changes in SF-36 scores from
baseline to endpoint were statistically signiﬁcant for tapentadol PR com-
pared with placebo for physical functioning, role-physical, bodily pain, and
the physical component summary scores (P≤0.029 for all comparisons).
In OA study 2, numerically greater improvements were observed with
tapentadol PR compared with placebo for the SF-36 physical functioning,
bodily pain, social functioning, role-emotional, and physical component
summary scores. In the DPN study, mean changes in SF-36 scores from
baseline to endpoint were statistically signiﬁcant for tapentadol PR com-
pared with placebo for role-physical, bodily pain, social functioning, and
physical component summary scores (all P≤0.012). In the pooled analysis
of SF-36 data from the 2 OA studies and the low back pain study, signiﬁcant
improvements were observed for tapentadol PR compared with placebo
for physical functioning (P<0.001), role-physical (P= 0.001), bodily pain
(P<0.001), vitality (P= 0.041), and physical component summary (P<0.001)
scores; no signiﬁcant improvements were observed for oxycodone CR
compared with placebo. In the low back pain study, OA study 1, and the
DPN study, signiﬁcantly greater improvements from baseline to endpoint
were observed in the EQ-5D health status index score with tapentadol PR
compared with placebo (all P≤0.020). In the pooled analysis of EQ-5D data
from the 2 OA studies and the low back pain study, a signiﬁcantly greater
improvement from baseline to endpoint in the EQ-5D health status index
score was seen with tapentadol PR compared with placebo (P<0.001) and
compared with oxycodone CR (P<0.001); a signiﬁcant improvement was
not observed for oxycodone CR compared with placebo.
Conclusions: Treatment with tapentadol PR (100-250 mg bid) was associ-
ated with signiﬁcant improvements in overall health and physical health
status compared with placebo across nociceptive and neuropathic pain
conditions.
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ASSESSMENT OF OPIOIDWITHDRAWAL IN PATIENTS TREATED WITH
TAPENTADOL PROLONGED RELEASE DURING AN OPEN-LABEL
EXTENSION STUDY
J. Ashworth1, B. Kuperwasser2, M. Etropolski2, B. Lange1, R. Lange1,
T. Häufel3
1Global Dev., Grünenthal GmbH, Aachen, Germany; 2Johnson & Johnson
Pharmaceutical Res. & Dev., L.L.C., Raritan, NJ; 3Global Drug Safety, Grünenthal
GmbH, Aachen, Germany
Purpose: Opioid withdrawal following treatment with tapentadol pro-
longed release (PR) was evaluated in this 1-year open-label extension study
(ClinicalTrials.gov Identiﬁer: NCT00487435).
Methods: Patients were eligible for enrollment if they completed 1 of
4 phase 3 studies: two 15-week studies that evaluated the eﬃcacy of
tapentadol PR and oxycodone controlled release (CR) compared with
placebo for chronic osteoarthritis pain (NCT00421928) or low back pain
(NCT00449176), a crossover study (two 2-week periods following a 3-week
titration with tapentadol immediate release) to assess dose conversion
between the immediate-release and prolonged-release tapentadol formu-
lations in patients with chronic low back pain (NCT00594516), or a 1-year
controlled long-term safety study of tapentadol PR and oxycodone CR
in patients with chronic osteoarthritis or low back pain (NCT00361504).
Patients who successfully completed one of the eﬃcacy or crossover studies
or who received oxycodone CR in the 1-year safety study were titrated to
their optimal therapeutic dose of tapentadol PR (100-250 mg bid) during
a titration period of up to 4 weeks then continued on their optimal dose
for up to 48 weeks during the maintenance period. Patients who received
tapentadol PR in the 1-year safety study continued on their optimal dose
determined in the parent study. The Clinical Opiate Withdrawal Scale
(COWS; 11-item scale scored from 0-48; <5 = no withdrawal, 5-12 = mild,
13-24 = moderate, 25-36 = moderately severe, and >36 = severe) and the
Subjective Opiate Withdrawal Scale (SOWS; 15-item scale, possible score
of 0-60; 60 = severe withdrawal) were used to assess opioid withdrawal in
patients who did not take opioids after study drug discontinuation. COWS
and SOWS scores were summarized according to the time of the last study
drug intake. For the COWS, the categories were ≥2 days to <5 days and
≥5 days, and for the SOWS, the categories were 1, 2, 3, 4, and ≥5 days.
Treatment-emergent adverse events (TEAEs) were recorded throughout the
study.
Results: Of the 384 patients who had a COWS assessment from ≥2 to <5
days after study drug discontinuation, 88.8%, 10.7%, and 0.5% experienced
no withdrawal, mild withdrawal, or moderate withdrawal, respectively. Of
the 321 patients who had a COWS assessment ≥5 days after discontin-
uation of tapentadol PR, 90.7% had no withdrawal; mild and moderate
withdrawal were observed in 8.7% and 0.6% of these patients, respectively.
Based on results of COWS assessments, no patients experienced moderately
severe or severe withdrawal. Mean (standard deviation) SOWS scores were
as follows: 1 day (n = 2), 4.5 (2.12); 2 days (n = 536), 8.8 (9.48); 3
days (n = 556), 9.3 (9.99); 4 days (n = 561), 7.8 (9.24); ≥5 days (n =
552), 5.6 (7.20); mean SOWS scores for all time periods were low (<10),
indicating minimal opioid withdrawal. The most common TEAEs (reported
by ≥10% of patients [N = 1154]) were headache (13.1%), nausea (11.8%),
and constipation (11.1%).
Conclusions: Results of COWS assessments completed by investigators
≥2 to <5 days following study drug discontinuation indicate that the
majority of patients experienced no opioid withdrawal. SOWS assessments
completed by patients each day immediately following study drug discon-
tinuation also indicate a low incidence of withdrawal and suggest that
opioid withdrawal peaks between Days 3 and 5. These results are similar
to those shown previously following tapentadol PR treatment and are
similar to those shown for placebo in previous placebo-controlled studies
of tapentadol PR for chronic pain. Together, these results indicate that
long-term treatment with tapentadol PR (100-250 mg bid) for up to 1 year
in this open-label extension trial was associated with a low incidence of
opioid withdrawal following treatment discontinuation without tapering in
patients with moderate to severe chronic painful osteoarthritis or chronic
low back pain.
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TREATMENT OF CARTILAGE DEFECTS IN THE KNEE USING ALGINATE
BEADS CONTAINING HUMANMATURE ALLOGENIC CHONDROCYTES:
CLINICAL RESULTS AT 3 YEARS OF FOLLOW-UP
A.A. Dhollander, P.C. Verdonk, R. Verdonk, G. Verbruggen, K.F. Almqvist
Ghent Univ., Ghent, Belgium
Aim: The present study was designed to evaluate the implantation of
alginate beads containing human mature allogenic chondrocytes for the
treatment of symptomatic cartilage defects in the knee.
Methods: A biodegradable, alginate-based biocompatible scaffold contain-
ing human mature allogenic chondrocytes was used for the treatment
of chondral and osteochondral lesions in the knee. Twenty-one patients
were clinically prospectively evaluated with use of the Western Ontario
and McMaster Universities Osteoarthritis Index (WOMAC) and a Visual
Analogue Scale (VAS) for pain preoperatively and at 3, 6, 9, 12, 24 and 36
months of follow-up.
Results: A statistically signiﬁcant clinical improvement became apparent
after 6 months and patients continued to improve during the 36 months
of follow-up. Adverse reactions to the alginate/ﬁbrin matrix seeded with
the allogenic cartilage cells were not observed. Two of the procedures
failed. One of the patients had loosening of the periosteal ﬂap, which was
attributed to a failure of the surgical procedure. The other failure case was
the result of the poor quality and quantity of the repair tissue itself.
Discussion: The results of this pilot study show that the alginate-based
scaffold containing human mature allogenic chondrocytes is feasible for
the treatment of symptomatic cartilage defects in the knee. The described
technique provides clinical outcomes equal to those of other cartilage
repair techniques.
